Compile Data Set for Download or QSAR
Report error Found 23 Enz. Inhib. hit(s) with all data for entry = 50008001
TargetChymotrypsinogen A(Bovine)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070010(4-((2R,3R)-1-Benzylcarbamoyl-3-methyl-4-oxo-azetid...)
Affinity DataIC50: 1.60E+3nMAssay Description:Concentration required to inhibit the mammalian Chymotrypsinogen by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070012(Acetic acid (2R,3R)-1-benzylcarbamoyl-3-methyl-4-o...)
Affinity DataIC50: 6.50E+3nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070014((2R,3R)-2-[4-(2,2-Dimethyl-propionyl)-phenoxy]-3-m...)
Affinity DataIC50: 1.70E+4nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070010(4-((2R,3R)-1-Benzylcarbamoyl-3-methyl-4-oxo-azetid...)
Affinity DataIC50: 2.00E+4nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070009(Acetic acid (2R,3S)-1-benzylcarbamoyl-3-methyl-4-o...)
Affinity DataIC50: 2.70E+4nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070011(Acetic acid (R)-1-benzylcarbamoyl-4-oxo-azetidin-2...)
Affinity DataIC50: 4.20E+4nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070013(4-((2R,3R)-1-Benzylcarbamoyl-3-ethyl-4-oxo-azetidi...)
Affinity DataIC50: 5.00E+4nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070016(Acetic acid (R)-1-butylcarbamoyl-4-oxo-azetidin-2-...)
Affinity DataIC50: 6.80E+4nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070020(Acetic acid (2R,3R)-3-methyl-4-oxo-1-phenylcarbamo...)
Affinity DataIC50: 8.60E+4nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070026(4-((R)-1-Benzylcarbamoyl-4-oxo-azetidin-2-yloxy)-b...)
Affinity DataIC50: 1.00E+5nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070007(Acetic acid (R)-1-benzylcarbamoyl-3,3-dimethyl-4-o...)
Affinity DataIC50: 1.00E+5nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070025(4-((2R,3S)-1-Benzylcarbamoyl-3-ethyl-4-oxo-azetidi...)
Affinity DataIC50: 1.00E+5nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070021(Acetic acid (R)-3,3-diethyl-1-methylcarbamoyl-4-ox...)
Affinity DataIC50: 1.00E+5nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetChymotrypsinogen A(Bovine)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070014((2R,3R)-2-[4-(2,2-Dimethyl-propionyl)-phenoxy]-3-m...)
Affinity DataIC50: 1.00E+5nMAssay Description:Concentration required to inhibit the mammalian Chymotrypsinogen by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070023(4-((R)-4-Oxo-1-phenylcarbamoyl-azetidin-2-yloxy)-b...)
Affinity DataIC50: 1.00E+5nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAcetylcholinesterase(Human)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070010(4-((2R,3R)-1-Benzylcarbamoyl-3-methyl-4-oxo-azetid...)
Affinity DataIC50: 1.00E+5nMAssay Description:Concentration required to inhibit the mammalian Acetylcholinesterase by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070022((2R,3S)-2-[4-(2,2-Dimethyl-propionyl)-phenoxy]-3-m...)
Affinity DataIC50: 1.00E+5nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070018(Acetic acid (R)-1-isopropylcarbamoyl-4-oxo-azetidi...)
Affinity DataIC50: 1.00E+5nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070019(Acetic acid (R)-1-ethylcarbamoyl-4-oxo-azetidin-2-...)
Affinity DataIC50: 1.00E+5nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAcetylcholinesterase(Human)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070014((2R,3R)-2-[4-(2,2-Dimethyl-propionyl)-phenoxy]-3-m...)
Affinity DataIC50: 1.00E+5nMAssay Description:Concentration required to inhibit the mammalian Acetylcholinesterase by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070017(4-((2R,3S)-1-Benzylcarbamoyl-3-methyl-4-oxo-azetid...)
Affinity DataIC50: 1.00E+5nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070015(Acetic acid (2R,3S)-3-methyl-4-oxo-1-phenylcarbamo...)
Affinity DataIC50: 1.00E+5nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetCapsid scaffolding protein(HHV-5)
Glaxo Wellcome Research and Development

Curated by ChEMBL
LigandPNGBDBM50070008(4-((R)-1-Isopropylcarbamoyl-4-oxo-azetidin-2-yloxy...)
Affinity DataIC50: 1.00E+5nMAssay Description:Concentration required to inhibit the mutant alpha-Ala HCMV protease by 50% was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed